Ontario is providing a $1.7 million investment to support life sciences innovation at Piramal Pharma’s drug substance facility in Aurora, according to multiple reports.
The funding is described as being delivered through Ontario’s Life Sciences Scale-Up Fund. Piramal Pharma Solutions is also investing more broadly in its Aurora site, with one report stating the company is putting over $5.3 million into upgrades to site infrastructure. Together, the public and private investments are intended to advance manufacturing and innovation capacity for healthcare-related products.
Both sources frame the announcement as part of Ontario’s broader efforts to strengthen the province’s life sciences and healthcare sector. While the reports emphasize the scale-up funding mechanism and the company’s additional capital improvements, they do not provide differing accounts of the project’s basic purpose, location, or the amounts cited.
